CTMX
CytomX Therapeutics Inc
2.70$
-1.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 91.5% | 96.2% | 94.5% | 97.7% | 97.5% | 88.9% | 90.3% | 91.4% | 90.9% | 90.7% | 89.0% | 95.0% | |
| 88.1% | 30.3% | 52.6% | 44.6% | 54.2% | 55.2% | 53.5% | 60.6% | 74.2% | 8.5% | 31.6% | 8.4% | |
| 88.1% | 94.7% | 91.4% | 94.1% | 95.4% | 86.8% | 88.1% | 89.9% | 74.2% | 86.5% | 83.5% | 90.4% | |
| 2.6% | 0.4% | 1.2% | 2.5% | 0.0% | 0.0% | 0.2% | 0.2% | 13.8% | 1.7% | 2.6% | 1.3% | |
| 0.1% | 0.0% | 0.0% | 0.0% | – | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | |
| 4.1% | 1.8% | 2.2% | 1.1% | 1.5% | 9.6% | 1.9% | 1.8% | 2.3% | – | – | – | |
| 1.3% | 0.5% | 0.5% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | 0.4% | 0.5% | 0.8% | 0.6% | |
| 2.4% | 0.9% | 0.9% | 0.4% | 0.3% | 0.4% | 0.3% | 0.3% | 0.3% | 0.4% | 0.5% | 0.3% | |
| 207.5% | 36.1% | 60.6% | 82.4% | 71.4% | 85.0% | 102.2% | 73.7% | 132.9% | 123.5% | 100.4% | 34.7% | |
| 15.3% | 8.0% | 18.0% | 15.4% | 21.4% | 25.1% | 19.0% | 31.3% | 58.5% | 77.3% | 71.2% | 30.8% | |
| 1.9% | – | – | – | 2.9% | 0.8% | 0.9% | 1.1% | 1.6% | 2.3% | 4.3% | 2.8% | |
| 2.6% | 2.4% | 3.3% | 1.1% | 1.1% | 1.2% | 0.8% | 0.8% | 1.1% | 0.7% | 0.9% | 0.9% | |
| 2.1% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| -107.5% | 63.9% | 39.4% | 17.6% | 28.6% | 15.0% | -2.2% | 26.3% | -32.9% | -23.5% | -0.4% | 65.3% | |
| -106.9% | -59.6% | -88.6% | -55.2% | -68.9% | -122.3% | -141.6% | -157.3% | -277.1% | -358.5% | -573.8% | -469.7% | |
| 47.8% | 18.0% | 18.2% | 9.3% | 9.1% | 13.3% | 12.9% | 18.9% | 25.2% | 36.6% | 70.3% | 91.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.